- Home
- JXN vs NUVL Comparison
JXN vs NUVL Comparison
Compare JXN & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXN
- NUVL
- Stock Information
- Founded
- JXN 1961
- NUVL 2017
- Country
- JXN United States
- NUVL United States
- Employees
- JXN N/A
- NUVL N/A
- Industry
- JXN Life Insurance
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- JXN Finance
- NUVL Health Care
- Exchange
- JXN Nasdaq
- NUVL Nasdaq
- Market Cap
- JXN 6.8B
- NUVL 6.7B
- IPO Year
- JXN N/A
- NUVL 2021
- Fundamental
- Price
- JXN $92.54
- NUVL $75.84
- Analyst Decision
- JXN Hold
- NUVL Strong Buy
- Analyst Count
- JXN 5
- NUVL 11
- Target Price
- JXN $92.40
- NUVL $112.36
- AVG Volume (30 Days)
- JXN 578.0K
- NUVL 558.9K
- Earning Date
- JXN 02-19-2025
- NUVL 02-25-2025
- Dividend Yield
- JXN 3.02%
- NUVL N/A
- EPS Growth
- JXN N/A
- NUVL N/A
- EPS
- JXN N/A
- NUVL N/A
- Revenue
- JXN $4,063,000,000.00
- NUVL N/A
- Revenue This Year
- JXN N/A
- NUVL N/A
- Revenue Next Year
- JXN $4.08
- NUVL N/A
- P/E Ratio
- JXN N/A
- NUVL N/A
- Revenue Growth
- JXN 2072.73
- NUVL N/A
- 52 Week Low
- JXN $48.00
- NUVL $61.80
- 52 Week High
- JXN $115.22
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- JXN 54.38
- NUVL 38.09
- Support Level
- JXN $91.12
- NUVL $69.58
- Resistance Level
- JXN $91.89
- NUVL $78.18
- Average True Range (ATR)
- JXN 2.27
- NUVL 3.03
- MACD
- JXN 0.94
- NUVL 0.04
- Stochastic Oscillator
- JXN 86.49
- NUVL 50.40
About JXN Jackson Financial Inc.
Jackson Financial Inc helps Americans grow and protect their retirement savings and income to enable them to pursue financial freedom for life. Its retail products offerings comprise annuities, designed to help retail investors save for and live in retirement. Its diverse suite of annuities includes a variable, fixed index, and fixed annuities. It manages the business through three segments: Retail Annuities, Institutional Products, and Closed Life and Annuity Blocks and Corporate and Other segments.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.